Lab test launched for early detection of Sjögren's syndrome

Article

Nicox has launched Sjö, an advanced diagnostic panel for the early detection of Sjögren's syndrome, and has formed a partnership with the Sjögren's Syndrome Foundation to raise aware of this disease among eye care professionals.

Nicox has launched Sjö, an advanced diagnostic panel for the early detection of Sjögren's syndrome, and has formed a partnership with the Sjögren's Syndrome Foundation to raise aware of this disease among eye care professionals.

Sjö is a proprietary laboratory test developed by Immco Diagnostics Inc. that combines traditional markers with three novel, proprietary biomarkers, which allow for earlier detection of Sjögren's syndrome.

Statistics support the prevalence and need for timely and correct diagnosis of Sjögren's syndrome, one of the most common and underdiagnosed autoimmune diseases. Sjögren's syndrome can lead to significant morbidity, diminished gland performance, and atrophy, and is estimated to affect 4 million people in the US, of which 3 million are undiagnosed.

Indeed, further estimates hold that of the 20 million patients aged 40 years and older who suffer from dry eyes in the US, 1 in 10 may also have Sjögren's syndrome. In addition, there is an average delay of 4.7 years for patients to receive an accurate diagnosis of Sjögren's syndrome, and they are often diagnosed in the late stages of the disease.

One of the early hallmark symptoms of this disease is the attacking of moisture-producing glands by a patient's immune cells, resulting in dry eye symptoms. Since many Sjögren's patients first present to their eye care practitioner with dry eye symptoms, eye care practitioners have a unique and vital role in the early identification and diagnosis of this disease.

"The launch of a proprietary, novel test for early detection of Sjögren's Syndrome demonstrates the potential of ophthalmic diagnostics in a wide range of conditions… We are pleased to partner with the Sjögren's Syndrome Foundation to increase awareness of this serious and underdiagnosed condition among eye care practitioners across the country," said Jerry St. Peter, executive vice president and general manager, Nicox Inc.

"The Sjögren's Syndrome Foundation is honored to be partnering with Nicox as they unveil their new Sjögren's diagnostic," said Steven Taylor, chief executive officer of the Sjögren’s Syndrome Foundation. "This partnership will help educate eye care professionals about the seriousness of Sjögren's and encourage them to identify potential Sjögren's patients, enabling them to receive proper diagnosis and timely medical care to treat this serious autoimmune disease," he concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.